What do systematic reviews say?

Number of women reporting adverse events ‐ not reported · women with urinary incontinence

Serious adverse events during the study period · children with acute postoperative pain

Serious adverse events during the study period · children with acute postoperative pain

Adverse Events ‐ reported, but not analyzed in this review · Apathy in people with mild‐to‐moderate Alzheimer's disease

Adverse events associated with RIC treatment ‐ not reported · people with ischaemic stroke

Specific adverse events: thromboembolic events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

Serious adverse events/death: long‐term outcomes ‐ not reported · rehabilitation (long‐term outcomes)

Serious adverse events or complications of treatment — not reported

Short‐term impact (< 12 months) unintended adverse events ‐ not reported · children aged 5 years and under

Proportion of participants with ≥ 1 serious adverse events ‐ not reported · adults with biliary sphincter of Oddi dysfunction

Severe adverse events or withdrawals (due to adverse events) ‐ not reported · People with hip or knee osteoarthritis

Proportion of participants with ≥ 1 non‐serious adverse events ‐ not reported · adults with biliary sphincter of Oddi dysfunction

Proportion of participants with ≥ 1 non‐serious adverse events ‐ not reported · adults with biliary sphincter of Oddi dysfunction

Proportion of participants with ≥ 1 non‐serious adverse events ‐ not reported · adults with biliary sphincter of Oddi dysfunction

Number of adverse events requiring discontinuation of treatment ‐ not reported · treating infections in people with neutropenia or neutrophil dysfunction

Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

Minor adverse events not leading to withdrawal of treatment · pityriasis rosea

Adverse events: clinically relevant non‐major bleeding / heparin‐induced thrombocytopenia ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures

Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures